Allergan plc (NYSE:AGN) Director Nesli Basgoz sold 1,889 shares of the business’s stock in a transaction that occurred on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total value of $416,430.05. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Allergan plc (NYSE:AGN) traded up 0.18% on Monday, hitting $219.52. The company’s stock had a trading volume of 1,770,195 shares. The company has a 50 day moving average price of $236.44 and a 200-day moving average price of $222.55. Allergan plc has a 1-year low of $184.50 and a 1-year high of $261.27. The company has a market capitalization of $73.73 billion, a P/E ratio of 6.84 and a beta of 1.07.

Allergan plc (NYSE:AGN) last released its quarterly earnings results on Tuesday, May 9th. The company reported $3.35 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.32 by $0.03. Allergan plc had a net margin of 100.04% and a return on equity of 7.21%. The business had revenue of $3.57 billion for the quarter, compared to analysts’ expectations of $3.53 billion. During the same period in the prior year, the firm earned $3.04 earnings per share. Allergan plc’s revenue was up 5.1% compared to the same quarter last year. On average, equities analysts forecast that Allergan plc will post $16.10 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 15th. Stockholders of record on Thursday, May 18th will be paid a dividend of $0.70 per share. The ex-dividend date is Tuesday, May 16th. This represents a $2.80 annualized dividend and a dividend yield of 1.28%.

WARNING: This article was originally published by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/05/22/nesli-basgoz-sells-1889-shares-of-allergan-plc-agn-stock.html.

Several hedge funds have recently added to or reduced their stakes in the stock. Appaloosa LP boosted its stake in Allergan plc by 249.8% in the fourth quarter. Appaloosa LP now owns 4,261,406 shares of the company’s stock valued at $894,938,000 after buying an additional 3,043,097 shares during the period. Janus Capital Management LLC boosted its stake in Allergan plc by 20.5% in the fourth quarter. Janus Capital Management LLC now owns 3,897,873 shares of the company’s stock valued at $818,699,000 after buying an additional 663,390 shares during the period. Baupost Group LLC MA boosted its stake in Allergan plc by 71.5% in the fourth quarter. Baupost Group LLC MA now owns 3,432,603 shares of the company’s stock valued at $720,881,000 after buying an additional 1,430,625 shares during the period. Norges Bank bought a new stake in Allergan plc during the fourth quarter valued at approximately $682,333,000. Finally, Veritas Asset Management LLP bought a new stake in Allergan plc during the first quarter valued at approximately $761,339,000. 86.40% of the stock is currently owned by institutional investors and hedge funds.

AGN has been the subject of several analyst reports. Vetr upgraded Allergan plc from a “hold” rating to a “buy” rating and set a $224.07 price objective for the company in a research report on Monday, January 23rd. Deutsche Bank AG boosted their price objective on Allergan plc from $262.00 to $265.00 and gave the stock a “buy” rating in a research report on Tuesday, March 28th. Royal Bank of Canada set a $279.00 price objective on Allergan plc and gave the stock a “buy” rating in a research report on Wednesday, April 12th. Piper Jaffray Companies set a $205.00 price objective on Allergan plc and gave the stock a “hold” rating in a research report on Wednesday, February 22nd. Finally, Leerink Swann boosted their price objective on Allergan plc to $280.00 and gave the stock a “buy” rating in a research report on Thursday, February 9th. Six research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $267.21.

About Allergan plc

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

12 Month Chart for NYSE:AGN

Receive News & Ratings for Allergan plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan plc and related companies with MarketBeat.com's FREE daily email newsletter.